From each FDA label

Do GLP-1s cause stomach pain?

Stomach pain is in the main trial table of 8 labels. The highest rate printed is 20% on Wegovy 2.4 mg (10% on placebo) and the lowest 5% on Mounjaro 15 mg (4% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 27, 2026.

Rate against placebo

How often stomach pain happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Wegovy2.4 mg20%10%+10 pointsDailyMed
Foundayo17.2 mg14%7%+7 pointsDailyMed
Rybelsus and Ozempic tablets14 mg11%4%+7 pointsDailyMed
Zepbound15 mg10%5%+5 pointsDailyMed
Trulicity1.5 mg9.4%4.9%+4.5 pointsDailyMed
Ozempic1 mg5.7%4.6%+1.1 pointsDailyMed
Saxenda3 mg5.4%3.1%+2.3 pointsDailyMed
Mounjaro15 mg5%4%+1 pointsDailyMed
Word for word

What each label says about stomach pain

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that occurred at a higher incidence among Wegovy injection-treated adult patients included dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, gastritis, hemorrhoids, and hiccups.
  • The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related reactions that occurred at a higher incidence than placebo among Wegovy injection-treated pediatric patients included abdominal pain, constipation, eructation, gastroesophageal reflux disease, dyspepsia, and flatulence.

Label revised Jun 18, 2026. DailyMed

Mounjaro

  • In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to Mounjaro, adverse reactions reported with Mounjaro were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%).
  • The incidences of adverse reactions reported in pediatric patients treated with Mounjaro 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia.
  • During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, Mounjaro 5 mg, and 10 mg, respectively.

Label revised Aug 27, 2026. DailyMed

Saxenda

  • The percentage of patients reporting nausea declined as treatment continued. Other common adverse reactions that occurred at a higher incidence among Saxenda-treated patients included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, eructation and abdominal distension.

Label revised Feb 25, 2026. DailyMed

Byetta: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Ozempic, Rybelsus and Ozempic tablets, Zepbound, Foundayo, Trulicity, Victoza: no finding on this in the sections read here.

Not from trials

Reports to FDA about stomach pain

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicUpper abdominal pain: 2,960 · Abdominal pain: 2,24070,863
TrulicityUpper abdominal pain: 2,479 · Abdominal pain: 2,38887,279
MounjaroUpper abdominal pain: 2,221 · Abdominal pain: 2,06597,440
ZepboundUpper abdominal pain: 1,912 · Abdominal pain: 73680,835
VictozaUpper abdominal pain: 1,290 · Abdominal pain: 1,06941,462
ByettaUpper abdominal pain: 1,257 · Abdominal pain: 79352,087
WegovyUpper abdominal pain: 770 · Abdominal pain: 60725,993
Rybelsus and Ozempic tabletsAbdominal pain: 299 · Upper abdominal pain: 2867,758
SaxendaUpper abdominal pain: 220 · Abdominal pain: 1957,270
FoundayoUpper abdominal pain: 137 · Abdominal pain: 443,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Stomach pain on a GLP-1: common questions

Which GLP-1 causes the most stomach pain?

No trial here ranks them. By the rates each label prints, Wegovy 2.4 mg is highest at 20% (placebo 10%) and Mounjaro 15 mg lowest at 5% (placebo 4%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Wegovy cause stomach pain?

In its FDA label, 20% of people taking Wegovy 2.4 mg reported stomach pain, against 10% on placebo.

Does Foundayo cause stomach pain?

In its FDA label, 14% of people taking Foundayo 17.2 mg reported stomach pain, against 7% on placebo.

Does Rybelsus cause stomach pain?

In its FDA label, 11% of people taking Rybelsus and Ozempic tablets 14 mg reported stomach pain, against 4% on placebo.

Does Zepbound cause stomach pain?

In its FDA label, 10% of people taking Zepbound 15 mg reported stomach pain, against 5% on placebo.

Does Trulicity cause stomach pain?

In its FDA label, 9.4% of people taking Trulicity 1.5 mg reported stomach pain, against 4.9% on placebo.

Does Ozempic cause stomach pain?

In its FDA label, 5.7% of people taking Ozempic 1 mg reported stomach pain, against 4.6% on placebo.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.